## AMENDMENTS TO THE CLAIMS

Please cancel claims 1-14, 22, 27, 28, 33, 37, 41 and 42 and add the following new claims. A complete listing of the claims, including their status identifier, is set forth below.

## 1-44. (Cancelled)

- 45. (New) A cyclic peptide comprising:
  - a) a chaperone binding region; and
  - b) a target binding region of wholly or partially unknown sequence

wherein said chaperone binding region is known to interact with an intracellular polypeptide to form a complex.

- 46. (New) The cyclic peptide of claim 45, wherein said complex presents said target binding region to other polypeptides in a cell.
- (New) The cyclic peptide of claim 45, wherein said target binding region has a random amino acid sequence.
- 48. (New) The cyclic peptide of Claim 45, wherein said cyclic peptide consists of genetically encoded amino acids.
- (New) The cyclic peptide of Claim 45, wherein said chaperone binding region binds an immunophilin.
- 50. (New) The cyclic peptide of Claim 49, wherein said immunophilin is cyclophilin or an FK-binding protein.
- (New) The cyclic peptide of Claim 50, wherein said FK-binding protein is selected from the group consisting of FKBP12, FKBP13, FKBP25, and FKBP59.

- (New) The cyclic peptide of Claim 45, wherein said chaperone binding region comprises an amino acid sequence selected from a group consisting of Ala-Gly-Pro-Ile and or Leu-Pro.
- (New) A method of identifying a cyclic peptide capable of altering a phenotype of a cell comprising:
  - a) administering to the cell a cyclic peptide of claim 45; and
  - b) assessing whether a phenotype of the cell has been altered.
- (New) The method of claim 53, wherein said cell comprises an endogenous intracellular polypeptide to which said chaperone binding region binds.
- 55. (New) The method of claim 53, wherein said cell comprises an exogenous intracellular polypeptide to which said chaperone binding region binds.
- (New) The method of claim 53, wherein said chaperone binding region interacts with an
  immunophilin.
- (New) The method of Claim 53, wherein said administering is done by administering to the cells a polynucleotide capable of expressing said cyclic peptide in said cell.
- 58. (New) A method of identifying a cyclic peptide capable of altering a phenotype of a cell, comprising:

administering to a plurality of cells a plurality of cyclic peptides of claim 45; identifying a cell exhibiting an altered phenotype; and determining the sequence of the target binding set of said cyclic peptide in said cell.